Floatz logo

Mogamulizumab

Adult T-Cell Leukemia/Lymphoma

Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Adult T-Cell Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Dexasone
The First Affiliated Hospital of Soochow University
Phase 2BBB
Fludarabine
John Reneau
Phase 2BBB
Cyclophosphamide
John Reneau
Phase 4BBB
Etoposide
National Cancer Institute (NCI)
Phase 2BBB
Rituximab
Northwestern University
Phase 2BBB

View all 50 →

Same molecule, other indications

Mogamulizumab is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
mycosis fungoidesActive
BB
Indicative · Phase 2
65 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →